文献速递贫血与红细胞疾病

炎症性贫血

Anemia of inflammation.
PubMed 文献 · Blood · 2018-11-06

炎症性贫血(AI)又称慢性病贫血,是住院和慢性病患者中最常见的贫血,见于感染、自身免疫病、肿瘤、慢性肾脏病、心力衰竭、慢性肺病和肥胖等。炎症细胞因子和铁调素导致铁限制性红细胞生成,诊断需排除其他病因并结合铁代谢指标。治疗基础疾病外,铁剂联合促红细胞生成素可改善贫血,靶向铁调素的药物可能提供新选择。

要点

  • 炎症性贫血是住院和慢性病患者中最常见的贫血类型。
  • 炎症细胞因子和铁调素导致铁限制性红细胞生成。
  • 铁剂联合促红细胞生成素可改善许多患者的贫血。

核心结论

  • 炎症性贫血是住院和慢性病患者中最常见的贫血,由炎症细胞因子和铁调素导致铁限制性红细胞生成,治疗基础疾病外铁剂联合促红细胞生成素可改善贫血,靶向铁调素的药物可能提供新选择。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • 炎症性贫血见于感染、自身免疫病、肿瘤、慢性肾脏病、充血性心力衰竭、慢性肺病和肥胖等患者。
  • 炎症诱导的细胞因子和铁调素阻断肠道铁吸收并导致铁滞留于网状内皮细胞,引起铁限制性红细胞生成。
  • 红细胞半衰期缩短、促红细胞生成素对贫血的反应受抑、炎症介质抑制红系细胞分化也参与发病。
  • 诊断需排除其他病因,并依据铁代谢特征性改变、低铁血症和高铁蛋白血症支持;合并铁缺乏时诊断更困难。

关键数值与推荐

  • 原文未报告具体诊断阈值或推荐等级。

临床怎么用

  • 除治疗基础疾病外,铁剂联合促红细胞生成素可改善许多患者的贫血。
  • 靶向铁调素并重新分配内源性铁用于红细胞生成的药物可能提供额外选择。
  • 需提高对贫血在各疾病中对患者 morbidity 贡献及贫血治疗对预后影响的理解和平衡考虑,以确定特定治疗的合适指征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anemia of inflammation (AI), also known as anemia of chronic disease (ACD), is regarded as the most frequent anemia in hospitalized and chronically ill patients. It is prevalent in patients with diseases that cause prolonged immune activation, including infection, autoimmune diseases, and cancer. More recently, the list has grown to include chronic kidney disease, congestive heart failure, chronic pulmonary diseases, and obesity. Inflammation-inducible cytokines and the master regulator of iron homeostasis, hepcidin, block intestinal iron absorption and cause iron retention in reticuloendothelial cells, resulting in iron-restricted erythropoiesis. In addition, shortened erythrocyte half-life, suppressed erythropoietin response to anemia, and inhibition of erythroid cell differentiation by inflammatory mediators further contribute to AI in a disease-specific pattern. Although the diagnosis of AI is a diagnosis of exclusion and is supported by characteristic alterations in iron homeostasis, hypoferremia, and hyperferritinemia, the diagnosis of AI patients with coexisting iron deficiency is more difficult. In addition to treatment of the disease underlying AI, the combination of iron therapy and erythropoiesis-stimulating agents can improve anemia in many patients. In the future, emerging therapeutics that antagonize hepcidin function and redistribute endogenous iron for erythropoiesis may offer additional options. However, based on experience with anemia treatment in chronic kidney disease, critical illness, and cancer, finding the appropriate indications for the specific treatment of AI will require improved understanding and a balanced consideration of the contribution of anemia to each patient's morbidity and the impact of anemia treatment on the patient's prognosis in a variety of disease settings.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Weiss G, Ganz T, Goodnough LT, et al. Anemia of inflammation. Blood. 2018. PMID: 30401705. doi:10.1182/blood-2018-06-856500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。